Top

Published in:

Open Access 01-12-2019 | Idiopathic Pulmonary Fibrosis | Research

Validation of the IPF-specific version of St. George’s Respiratory Questionnaire

Authors: Thomas Skovhus Prior, Nils Hoyer, Saher Burhan Shaker, Jesper Rømhild Davidsen, Janelle Yorke, Ole Hilberg, Elisabeth Bendstrup

Published in: Respiratory Research | Issue 1/2019

Abstract

Background

Patients with idiopathic pulmonary fibrosis (IPF) have impaired health-related quality of life (HRQL). To measure HRQL, an IPF-specific version of the St. George’s Respiratory Questionnaire (SGRQ-I) was developed, but not sufficiently validated. This study aimed to assess the validity (i.a. known-groups validity and concurrent validity) and test-retest reliability of SGRQ-I in IPF patients with different disease durations.

Methods

Patients with IPF were consecutively recruited and completed SGRQ, SGRQ-I, King’s Brief Interstitial Lung Disease questionnaire (K-BILD), University of California, San Diego Shortness of Breath Questionnaire (SOBQ) and Short Form-36 (SF-36) along with pulmonary function tests and a 6-min walk test (6MWT) at baseline. After two weeks, SGRQ-I and Global Rating of Change Scales (GRCS) were completed.

Results

At baseline and after two weeks, 150 and 134 patients completed the questionnaires, respectively. The internal consistency of SGRQ-I was high (Cronbach’s α = 0.92). Good concurrent validity was demonstrated by high intraclass correlation coefficients (ICC = 0.97), Bland-Altman plots and moderate to strong correlations to K-BILD, SOBQ and SF-36 (r = − 0.46 to 0.80). High ICC (0.92) and a Bland-Altman plot indicated good test-retest reliability. SGRQ-I was good at discriminating between patients with different stages of disease (Δscore > 18.1, effect sizes > 0.10). Validity was similar across groups of different disease duration.

Conclusions

SGRQ-I proved to be valid at distinguishing between different disease severities, valid compared to other HRQL instruments, applicable across different disease durations and reliable upon repetition. SGRQ-I is a valid option for measuring HRQL in patients with IPF.

Trial registration

The study was registered at clinicaltrials.org (NCT02818712) on 15 June 2016.

Available only for authorised users

Raghu G, Chen S-Y, Yeh W-S, Maroni B, Li Q, Lee Y-C, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir Med [Internet]. 2014;2600(14):1–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24875841.

Belkin A, Swigris JJ. Health-related quality of life in idiopathic pulmonary fibrosis: where are we now? Curr Opin Pulm Med [Internet]. 2013 Sep [cited 2015 Nov 29];19(5):474–479. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23851327.

Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med [Internet] 2016; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0954611116300191.

Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (London, England) [Internet] 2011 May 21 [cited 2016 Feb 21];377(9779):1760–1769. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21571362.

Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med [Internet]. 1993 Apr 15 [cited 2015 Oct 15];118(8):622–629. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8452328.

King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of Pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med [Internet]. 2014 May 29 [cited 2015 Oct 14];370(22):2083–2092. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24836312.CrossRef

Swigris JJ, Esser D, Conoscenti CS, Brown KK. The psychometric properties of the St George’s respiratory questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes [Internet] 2014;12(1):124. Available from: http://hqlo.biomedcentral.com/articles/10.1186/s12955-014-0124-1.

Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s respiratory questionnaire. Am Rev Respir Dis [Internet]. 1992 Jun [cited 2018 Jun 8];145(6):1321–1327. Available from: http://www.atsjournals.org/doi/abs/10.1164/ajrccm/145.6.1321.

Yorke J, Jones PW, Swigris JJ. Development and validity testing of an IPF-specific version of the St George’s respiratory questionnaire. Thorax [Internet]. 2010;65(10):921–926. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3697105&tool=pmcentrez&rendertype=abstract.

10.

Swigris JJ, Han M, Vij R, Noth I, Eisenstein EL, Anstrom KJ, et al. The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med [Internet]. 2012 Oct [cited 2015 Dec 15];106(10):1447–1455. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3441137&tool=pmcentrez&rendertype=abstract.

11.

Gries KS, Esser D, Wiklund I. Content validity of CASA-Q cough domains and UCSD-SOBQ for use in patients with Idiopathic Pulmonary Fibrosis. Glob J Health Sci [Internet]. 2013 Nov [cited 2016 Mar 7];5(6):131–141. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24171881

12.

Patel AS, Siegert RJ, Brignall K, Gordon P, Steer S, Desai SR, et al. The development and validation of the King’s brief interstitial lung disease (K-BILD) health status questionnaire. Thorax [Internet]. 2012;67(9):804–810. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22555278.CrossRef

13.

Capparelli I, Fernandez M, Saadia Otero M, Steimberg J, Brassesco M, Campobasso A, et al. Traducción al español y validación del cuestionario Saint George específico para fibrosis pulmonar idiopática. Arch Bronconeumol [Internet]. 2018 Nov 1 [cited 2017 Nov 9];54(2):68–73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29102341.

14.

WHO | WHO Definition of Palliative Care. WHO [Internet]. 2012 [cited 2018 Oct 16]; Available from: http://www.who.int/cancer/palliative/definition/en/.

15.

Kreuter M, Bendstrup E, Russell A-M, Bajwah S, Lindell K, Adir Y, et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med [Internet]. 2017 Dec [cited 2018 Oct 16];5(12):968–980. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2213260017303831.CrossRef

16.

Beaton DE, Bombardier C, Guillemin F, Ferraz MB, D.E. B, C. B, et al. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) [Internet]. 2000 Dec;25(24):3186–3191. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L32042951.

17.

Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Heal [Internet]. 2005;8(2):94–104. Available from: https://doi.org/10.1111/j.1524-4733.2005.04054.x.CrossRef

18.

Wells AU, Hirani N, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and new Zealand and the Irish thoracic society. Thorax [Internet] 2008 Sep 1 [cited 2019 Mar 29];63(Supplement 5):v1–58. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18757459.

19.

Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med [Internet]. 2011 Mar 15 [cited 2019 Feb 19];183(6):788–824. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21471066.

20.

Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med [Internet]. 2012 May 15 [cited 2016 Mar 8];156(10):684–691. Available from: http://annals.org/article.aspx?articleid=1157553.CrossRef

21.

Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest [Internet]. 1998 Mar [cited 2016 Jan 9];113(3):619–624. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9515834.

22.

Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care [Internet]. 1992 Jun [cited 2014 Jul 17];30(6):473–483. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1593914.

23.

Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther [Internet]. 2009;17(3):163–70 Available from: http://search.informit.com.au/documentSummary;dn=305401066726053;res=IELHEA.CrossRef

24.

Swigris JJ, Wilson H, Esser D, Conoscenti CS, Stansen W, Kline Leidy N, et al. Psychometric properties of the St George’s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials. BMJ Open Respir Res [Internet]. 2018 May 18 [cited 2018 Jun 7];5(1):e000278. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29862029.CrossRef

25.

Terwee CB, Bot SDM, de Boer MR, van der Windt DAWM, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42.CrossRef

26.

Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed: Lawrence Erlbaum Associates; 1988.

27.

McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res [Internet]. 1995 Aug [cited 2019 Aug 5];4(4):293–307. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7550178.

28.

Tzanakis N, Samiou M, Lambiri I, Antoniou K, Siafakas N, Bouros D. Evaluation of health-related quality-of-life and dyspnea scales in patients with idiopathic pulmonary fibrosis. Correlation with pulmonary function tests. Eur J Intern Med [Internet]. 2005;16(2):105–112. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15833676.CrossRef

29.

Swigris JJ, Wilson SR, Green KE, Sprunger DB, Brown KK, Wamboldt FS. Development of the ATAQ-IPF: a tool to assess quality of life in IPF. rcj [Internet]. 2010 Jan [cited 2015 Dec 18];8:77. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2920246&tool=pmcentrez&rendertype=abstract.

30.

Matsuda T, Taniguchi H, Ando M, Kondoh Y, Kimura T, Kataoka K, et al. COPD assessment test for measurement of health status in patients with idiopathic pulmonary fibrosis: a cross-sectional study. Respirology [Internet]. 2017 May [cited 2017 Nov 20];22(4):721–727. Available from: http://doi.wiley.com/10.1111/resp.12936.CrossRef

31.

Nagata K, Tomii K, Otsuka K, Tachikawa R, Otsuka K, Takeshita J, et al. Evaluation of the chronic obstructive pulmonary disease assessment test for measurement of health-related quality of life in patients with interstitial lung disease. Respirology [Internet]. 2012 Apr [cited 2018 Oct 17];17(3):506–512. Available from: http://doi.wiley.com/10.1111/j.1440-1843.2012.02131.x.CrossRef

32.

Grufstedt HK, Shaker SB, Konradsen H. Validation of the COPD Assessment Test (CAT) in patients with idiopathic pulmonary fibrosis. Eur Clin Respir J [Internet]. 2018 Jan 16 [cited 2018 Oct 30];5(1):1530028. Available from: https://www.tandfonline.com/doi/full/10.1080/20018525.2018.1530028.CrossRef

Title: Validation of the IPF-specific version of St. George’s Respiratory Questionnaire
Authors: Thomas Skovhus Prior
Nils Hoyer
Saher Burhan Shaker
Jesper Rømhild Davidsen
Janelle Yorke
Ole Hilberg
Elisabeth Bendstrup
Publication date: 01-12-2019
Publisher: BioMed Central
Keyword: Idiopathic Pulmonary Fibrosis
Published in: Respiratory Research / Issue 1/2019
Electronic ISSN: 1465-993X
DOI: https://doi.org/10.1186/s12931-019-1169-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2019

Vitamin D deficiency exacerbates bleomycin-induced pulmonary fibrosis partially through aggravating TGF-β/Smad2/3-mediated epithelial-mesenchymal transition

Primary pulmonary lymphoepithelioma-like carcinoma: a rare type of lung cancer with a favorable outcome in comparison to squamous carcinoma

Unique patterns of lower respiratory tract microbiota are associated with inflammation and hospital mortality in acute respiratory distress syndrome

Neutrophil elastase as a biomarker for bacterial infection in COPD

Insufficient serum L-ficolin is associated with disease presence and extent of pulmonary Mycobacterium avium complex disease

Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials